| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 |
| Sales | 791,000 | 647,000 | 785,000 | 1,005,000 | 1,093,000 |
| Sales Growth | +22.26% | -17.58% | -21.89% | -8.05% | +3.31% |
| Net Income | 205,000 | -148,000 | 134,000 | 275,000 | 58,000 |
| Net Income Growth | +238.51% | -210.45% | -51.27% | +374.14% | +65.71% |
Indivior Plc ADR (INVVY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Indivior PLC was incorporated in England and Wales on September 26, 2014 as a public limited company. It is a pharmaceutical company. It is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence.